Mizuho Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $38.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective lowered by Mizuho from $39.00 to $38.00 in a research report report published on Thursday morning, Benzinga reports. Mizuho currently has a neutral rating on the stock.

APLS has been the topic of a number of other reports. Robert W. Baird cut their target price on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a research report on Monday, September 23rd. HC Wainwright cut their target price on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their price target on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Friday, September 20th. Finally, The Goldman Sachs Group increased their target price on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $65.41.

Apellis Pharmaceuticals Trading Down 3.3 %

Shares of APLS stock opened at $26.68 on Thursday. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -7.71 and a beta of 0.87. The firm’s 50 day moving average price is $33.22 and its two-hundred day moving average price is $38.38. Apellis Pharmaceuticals has a fifty-two week low of $26.28 and a fifty-two week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The firm had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. Apellis Pharmaceuticals’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.02) EPS. On average, analysts anticipate that Apellis Pharmaceuticals will post -1.37 EPS for the current year.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Future Financial Wealth Managment LLC bought a new stake in shares of Apellis Pharmaceuticals in the 1st quarter valued at approximately $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals during the first quarter valued at about $89,000. nVerses Capital LLC increased its position in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. Finally, CWM LLC raised its position in Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after purchasing an additional 3,113 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).